Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer

NCT07062354 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT07062354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07062354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
March 25, 2026
Completion date
October 31, 2029
Enrollment
50 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

head & neck cancer, head & neck squamous cell carcinoma